Form 4: Director Elizabeth Mily Exercises Solventum RSUs

Director Elizabeth Mily acquired 3,403 shares of Solventum Corp common stock through the settlement of vested restricted stock units.

Summary

• Director Elizabeth Mily exercised 3,403 restricted stock units (RSUs) on April 30, 2026.
• The RSUs were settled for common stock at a price of $0 per share.
• Following the transaction, the director's total beneficial ownership of Solventum common stock increased to 9,009 shares.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event, as it represents the standard vesting of director compensation rather than a discretionary market trade.

Positives

• The transaction reflects the vesting of equity-based compensation, aligning the director's interests with shareholders.

Negatives

• None.

Risks

• None.

Future Outlook

Not applicable as this is a routine disclosure of insider equity transactions.

Industry Context

StockSavvy.ai notes that routine RSU vesting and settlement for corporate directors is standard practice and generally does not signal a change in corporate strategy or market outlook.

Comparison to Industry Standards

• The transaction is consistent with standard executive and director compensation practices in the healthcare and medical technology sectors.

Stakeholder Impact

• Minimal impact on shareholders as this is a routine equity settlement.

Next Steps

• None.

Key Dates

Keywords

Solventum, SOLV, Form 4, Insider Trading, Director Ownership, Restricted Stock Units